Schizophrenia Research
Volume 58, Issue 1 , Pages 55-62 , 1 November 2002

Elevated plasma level of apolipoprotein D in schizophrenia and its treatment and outcome

  • Sahebarao P Mahadik

      Affiliations

    • Corresponding Author InformationCorresponding author. Medical Research Service (242), Veterans Affairs Medical Center, 5B-103, 1 Freedom Way, Augusta, GA 30910, USA. Tel.: +1-706-733-0188x2490; fax: +1-706-823-3977
    • Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta, GA 30912, USA
    • Medical Research and Mental Health Service Lines, Veterans Affairs Medical Center, Augusta, GA 30910, USA
    • ,
  • Mohammad M Khan

      Affiliations

    • Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta, GA 30912, USA
    • ,
  • Denise R Evans

      Affiliations

    • Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta, GA 30912, USA
    • Medical Research and Mental Health Service Lines, Veterans Affairs Medical Center, Augusta, GA 30910, USA
    • ,
  • Vinay V Parikh

      Affiliations

    • Department of Psychiatry and Health Behavior, Medical College of Georgia, Augusta, GA 30912, USA

Received 21 August 2001 ,Revised 11 October 2001 ,Accepted 14 October 2001.

References 

  1. Axelrod J. Receptor-mediated activation of phospholipase A2 and arachidonic release in signal transduction. Biochem. Soc. Trans. 1990;8:503–507
  2. Bloom F. Advancing neurodevelopmental origin of schizophrenia. Arch. Gen. Psychiatry. 1993;50:224–227
  3. Boyles JK, Notterpek LM, Wardell MR, Rall SC. Identification, characterization, and tissue distribution of apolipoprotein D in the rat. J. Lipid Res. 1990;31:2243–2256
  4. Coyle JT, Putfarcken C. Oxidative stress, glutamate and neurodegenerative disorders. Science. 1993;262:689–695
  5. Essali MA, Das R, de Belleroche J, Hirsch SR. The platelet phosphoinositide system in schizophrenia: the effects of neuroleptic treatment. Biol. Psychiatry. 1990;28:478–487
  6. Evans DR, Mahadik SP, Akin J, Evans W, Jain D. Cell membrane essential fatty acid status in drug-naı̈ve first-episode psychotic patients and its relation to outcome. Schizophr. Res. 2001;49:83
  7. Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol. Psychiatry. 2000;47:8–21
  8. Franz G, Reindl M, Patel SC, Beer I, Unterrichter I, Berger T, et al. Increased expression of apolipoprotein D following experimental traumatic brain injury. J. Neurochem. 1999;73:1615–1625
  9. Herken H, Uz E, Ozyurt H, Sogut S, Virit O, Akoyl O. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol. Psychiatry. 2001;6:66–73
  10. Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr. Res. 1998;30:193–208
  11. Horrobin DF. The effects of antipsychotic drugs on membrane phospholipids—a possible novel mechanism of action of clozapine. In:  Peet M,  Glen AL,  Horrobin D editor. Phospholipid Spectrum Disorders in Psychiatry. Lancashire, UK: Marius Press; 1999;p. 113–117
  12. Horrobin DF, Manku MS, Hillman S, Glen IAM. Fatty acid levels in brains of schizophrenics and normal controls. Biol. Psychiatry. 1991;30:795–805
  13. Horrobin DF, Glen AIM, Glen EMT, Skinner F. Red cell membrane fatty acids in schizophrenic patients with mainly positive or mainly negative symptoms. Schizophr. Res. 1993;9:221
  14. Hudson CJ, Young LT, Li PP, Warsh JJ. CNS signal transduction in the pathophysiology and pharmacology of affective disorders and schizophrenia. Synapse. 1993;13:278–293
  15. Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JT, et al. Schizophrenia: manifestations, incidence and course in different cultures. Psychol. Med. Monogr. (Suppl). 1991;21:1–97
  16. Kaiya H, Nishida A, Imai A, Nakashima S, Nozawa Y. Accumulation of diacylglycerol in platelet phosphoinositides turnover in schizophrenia: a biological marker of good prognosis. Biol. Psychiatry. 1989;26:669–676
  17. Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu. Rev. Med. 2001;52:503–517
  18. Keshavan MS, Mallinger AG, Pettegrew JW, Dippold C. Erythrocyte membrane phospholipids in psychotic patients. Psychiatry Res. 1993;49:9–95
  19. Knipping G, Gogg-Fassolter G, Frohnwieser B, Krempler F, Kostner GM, Malle E. Quantification of apolipoprotein D by an immunoassay with time-resolved fluorescence spectroscopy. J. Immunol. Methods. 1997;202:85–95
  20. Li MX, Chlan-Fourney J, Juorio AV, Bennett VL, Shrikhande S, Keegan DL, et al. Differential effects of olanzapine on the gene expression of superoxide dismutase and low affinity nerve growth factor receptor. J. Neurosci. Res. 1999;56:72–75
  21. Liu Z, Chang GQ, Leibowitz SF. Apolipoprotein D interacts with the long-form leptin receptor: a hypothalamic function in the control of energy homeostasis. FASEB J. 2001;15:1329–1331
  22. Mahadik SP, Mukherjee S. Free radical pathology and the antioxidant defense in schizophrenia. Schizophr. Res. 1996;19:1–18
  23. Mahadik SP, Mukherjee S, Correnti E, Kelkar HS, Wakade CG, Costa RM, et al. Distribution of plasma membrane phospholipids and cholesterol in skin fibroblasts from drug-naı̈ve patients at the onset of psychosis. Schizophr. Res. 1994;3:239–247
  24. Mahadik SP, Mukherjee S, Horrobin D, Jenkins K, Correnti EE, Scheffer RE. Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar and normal controls. Psychiatry Res. 1996;63:133–142
  25. Mahadik SP, Mukherjee S, Correnti EE, Scheffer R, Mahadik J. Elevated plasma lipid peroxides at the onset of non-affective psychosis. Biol. Psychiatry. 1998;43:674–679
  26. Mahadik SP, Sitasawad V, Mulchandani M. Membrane peroxidation and the neuropathology of schizophrenia. In:  Horrobin D,  Glen AL,  Peet M editor. Phospholipid Spectrum Disorders in Psychiatric. Lancashire, UK: Marius Press; 1999;p. 99–111
  27. Mahadik SP, Evans D, Lal H. Oxidative stress and the role of antioxidant and ω-3 essential fatty acid supplementation in schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2001;25:463–493
  28. Mahadik SP, Evans DR, Terry A, Hill WD. Neuroprotective action of atypical antipsychotics in schizophrenia: improved cognitive performance and underlying mechanism of action. Schizophr. Res. 2001;49:94
  29. Mahadik SP, Evans DR, Terry A, Hill WD. Differential effects of risperidone and haloperidol on cognitive performance on rats and possible mechanism of action. Biol. Psychiatry. 2001;49:133S
  30. Morais-Cabral JHM, Atkins GL, Sanchez LM, Lopez-Boado YS, Lopez-Otin C, Sawyer L. Arachidonic acid binds to apolipoprotein D: implications for the protein's function. FEBS Lett. 1994;366:53–56
  31. Nasrallah HA. Neurodevelopmental pathogenesis of schizophrenia. Psychiatr. Clin. North Am. 1993;16:269–280
  32. Neuringer M, Conner WE, Lin DS, Barstad L, Luck S. Biochemical and functional effects of prenatal and post-natal ω-3 fatty acid deficiency on retina and brain in rhesus monkeys. Proc. Natl. Acad. Sci. U. S. A. 1986;83:4021–4025
  33. Ong WY, Lau CP, Leong SK, Kumar U, Suresh S, Patel SC. Apolipoprotein D gene expression in the rat brain and light and electron microscopic immunocytochemistry of apolipoprotein D expression in the cerebellum of neonatal immature and adult rats. Neuroscience. 1999;90:913–922
  34. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry. 1995;55:998–1007
  35. Overall JE, Gorham DR. Brief psychiatric rating scale. Psychol. Rep. 1962;10:799–812
  36. Pettegrew JW, Keshavan MS, Panchalingam K, Strychor S, Kaplan DB, Tretta MG, et al. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode drug-naı̈ve schizophrenics. A pilot study of the dorsal prefrontal cortex using in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch. Gen. Psychiatry. 1991;48:563–568
  37. Rassart E, Bedirian A, Carmo SD, Guinard O, Sirois J, Terrisse L, et al. Apolipoprotein D: a review. Biochim. Biophys. Acta. 2000;482:185–198
  38. Reddy R, Yao J. Free radical pathology in schizophrenia: a review. Prostaglandins, Leukotrienes Essent. Fatty Acids. 1996;55:33–43
  39. Reddy R, Keshavan MS, Yao JK. Reduced polyunsaturated fatty acids in first-episode neuroleptic-naı̈ve schizophrenia patients. Schizophr. Res. 2001;49:84
  40. Rotrosen J, Wolkin A. Phospholipid and prostaglandin hypotheses of schizophrenia. In:  Meltzer HY editors. Psychopharmacology: The Third Generation of Progress. New York: Raven Press; 1987;p. 759–764
  41. Sanchez LM, Diez-Itza I, Vizoso F, Lopez-Otin C. Cholesterol and apolipoprotein D in gross cystic disease of the breast. Clin. Chem. 1992;3:695–698
  42. Simonion NA, Coyle JT. Oxidative stress in neurodegenerative disease. Annu. Rev. Pharmacol. Toxicol. 1996;36:82–106
  43. Simopoulos AP. Omega-3 fatty acids in health and disease, and in growth and development. Am. J. Clin. Nutr. 1991;54:438–463
  44. Spreyer P, Schaal H, Kuhn G, Rothe T, Unterbeck A, Oleck K, et al. Regeneration-associated high levels expression of apolipoprotein D mRNA in endoneurial fibroblasts of peripheral nerve. EMBO J. 1990;9:2479–2484
  45. Stanley JA, Williamson PC, Drost DJ, Carr TJ, Rylett RJ, Malla A. An in vivo study of the prefrontal cortex of schizophrenic patients at different age of illness via phosphorous magnetic resonance spectroscopy. Arch. Gen. Psychiatry. 1995;52:399–406
  46. Thomas EA, Dean B, Pavey G, Sutcliffe JG. Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: implications for the pathophysiology of psychiatric disorder. Proc. Natl. Acad. Sci. U. S. A. 2001;98:4066–4071
  47. Thomas EA, Danielson PE, Nelson PA, Priby TM, Hilbush BS, Hasel KW, et al. Clozapine increases apolipoprotein D expression in rodent brain: towards a mechanism for neuroleptic pharmacotherapy. J. Neurochem. 2001;76:789–796
  48. Wainwright PE. Do essential fatty acids play a role in brain and behavioral development?. Neurosci. Biobehav. Rev. 1992;16:193–205
  49. Weinberger DR. On the plausibility of the ‘neurodevelopmental hypothesis’ of schizophrenia. Neuropsychopharmacology. 1996;14:1S–11S
  50. WHO . World Health Organization—The International Pilot Study of Schizophrenia. Geneva: WHO; 1973;
  51. Yao JK. Red blood cell and platelet fatty acid metabolism in schizophrenia. In:  Horrobin D,  Glen AL,  Peet M editor. Phospholipid Spectrum Disorders in Psychiatric. Lancashire, UK: Marius Press; 1999;p. 57–71
  52. Yao JK, Yasaei P, van Kammen DP. Increased turnover of platelet phosphatidylinositol in schizophrenia. Prostaglandins, Leukotrienes Essent. Fatty Acids. 1992;46:39–46
  53. Yao JK, van Kammen DP, Welker JA. Red cell membrane dynamics in schizophrenia: II. Fatty acid composition. Schizophr. Res. 1994;13:217–226
  54. Yao JK, Reddy R, van Kammen DP. Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. J. Psychiatr. Res. 1998;32:385–391
  55. Yao JK, Reddy R, van Kammen DP. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res. 1998;80:29–39
  56. Yao JK, Leonard S, Reddy R. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr. Res. 2000;42:7–17

PII: S0920-9964(01)00378-4

Schizophrenia Research
Volume 58, Issue 1 , Pages 55-62 , 1 November 2002

Article Tools

* Image Usage & Resolution